The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1471
Bellafill for Acne Scars
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Bellafill (Suneva), a dermal filler approved earlier for correction of nasolabial folds, has now also been approved by the FDA for correction of moderate to severe, atrophic, distensible facial acne scars on the cheek in adults ≥21 years old. It is the only dermal filler approved in the US for correction of facial acne scars.

MECHANISM OF ACTION — Bellafill contains 80% bovine collagen solution (including 0.3% lidocaine) and 20% non-resorbable polymethylmethacrylate (PMMA) microspheres. The collagen adds volume below pitted acne scars to lift them to the level of the surrounding skin, while the PMMA microspheres, according to the manufacturer, create a matrix that supports endogenous collagen production and provides long-term structural support.

A CLINICAL STUDY — Approval of Bellafill for atrophic facial acne scars was based on a double-blind trial in 147 patients with ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Bellafill for Acne Scars
Article code: 1471d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian